Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adagio Medical Holdings (ADGM) Depreciation & Amortization (CF) (2023 - 2026)

Adagio Medical Holdings (ADGM) reported Depreciation & Amortization (CF) of $210000.0 for Q1 2026, down 22.51% year-over-year from $271000.0 in Q1 2025, and down 11.39% on a QoQ basis from $237000.0 in Q4 2025.

Adagio Medical Holdings (ADGM) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $210000.0 in Q1 2026.

  • Quarterly Depreciation & Amortization (CF) fell 22.51% year-over-year to $210000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 27.02% YoY) and the FY2025 annual result came in at $970000.0, up 31.08% from the prior year.
  • Depreciation & Amortization (CF) fell to $210000.0 in Q1 2026 per ADGM's latest filing, from $237000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $500000.0 in Q3 2025 and bottomed at $100000.0 in Q3 2023.
  • The 4-year median for Depreciation & Amortization (CF) is $254000.0 (2025), against an average of $261300.0.
  • The widest annual swing landed in 2024, when Depreciation & Amortization (CF) jumped 216.0%; it then slumped 36.71% in 2025.
  • Tracing ADGM's Depreciation & Amortization (CF) over 4 years: stood at $133000.0 in 2023, then surged by 137.59% to $316000.0 in 2024, then dropped by 25.0% to $237000.0 in 2025, then fell by 11.39% to $210000.0 in 2026.
  • Per Business Quant, the three latest ADGM Depreciation & Amortization (CF) figures stand at $210000.0 (Q1 2026), $237000.0 (Q4 2025), and $500000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 381.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 120.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 749.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 351.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 40.90 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 67.10 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 78.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 123.40 Mn
10 Adagio Medical Holdings 16.86 Mn 3.95 Mn - 210,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 210,000.00
Mar 31, 2026 210,000.00
Dec 31, 2025 237,000.00
Dec 31, 2025 237,000.00
Sep 30, 2025 500,000.00
Sep 30, 2025 500,000.00
Jun 30, 2025 200,000.00
Jun 30, 2025 200,000.00
Mar 31, 2025 271,000.00
Mar 31, 2025 271,000.00
Sep 30, 2024 316,000.00
Sep 30, 2024 316,000.00
Jun 30, 2024 316,000.00
Jun 30, 2024 316,000.00
Mar 31, 2024 330,000.00
Mar 31, 2024 330,000.00
Dec 31, 2023 133,000.00
Dec 31, 2023 133,000.00
Sep 30, 2023 100,000.00
Sep 30, 2023 100,000.00